[ad_1]
|
||
| ▲ CEO Kim Hee-ryul of Heim Bio is explaining In-polymer. Source = Heim Bio | ||
HeimBio, which is undergoing clinical trials for the next-generation anticancer drug candidate, Daehan Cancer, has found an important clue to the possibility of developing Corona19 virus treatment without side effects based on research of inorganic polyphosphate in collaboration with Yonsei University Medical Research Team. Announced jointly with the Yonsei University Academic Cooperation-Medical Industry Group. The result of this study is the result of research by CEO Heim Bio Kim Hong-ryul with the research team at Yonsei University School of Medicine.
Heimbio CEO Kim Hee-ryul said: “We completed the patent application as a pharmaceutical composition for the prevention and treatment of infectious diseases by coronavirus. The patent was 100% agreed with the co-inventors in the transfer key to Heim Bio. It will soon be announced in detail through an international academic journal. ” We are also developing an anticancer drug for aerosol products using inpolymers and refractory molecular subtype cancer. In the future, we plan to continue research from various perspectives that require the development of coronavirus treatments and vaccines. “
Phosphorous polymers are known to have been approved by the Food and Drug Administration (FDA) as additives for food and pharmaceuticals and have been shown to be stable.
President Hong Ryeol Kim said: “As a result of observing at Yonsei University how coronavirus phosphate polymers of various chain lengths act on coronaviruses at different concentrations, we have received samples from definitive corona samples19. “At the same level, we have discovered a new fact that coronavirus replication is inhibited in host cells.”
The researchers reported the results to Dr. Massimo Zollo of CEINGE, a biotechnology research center located in Naples, Italy, in an experiment conducted in Korea using an oropharyngeal cell virus from a specimen from an Italian confirmatory corona19. The same phosphorous polymer sample used was analyzed for comparison.
 |
||
| ▲ The research team of Dr. Massimo Zollo, CEINGE of the Italian Institute of Biotechnology, is taking a commemorative photo. Source = Heim Bio | ||
“We were able to discover that the nucleotide sequence of various parts has already changed by comparing and analyzing the gene sequence of the promising sample collected from various European countries, including Italy and Italy,” said Kim. On this basis, in-depth research into the variation of viral replication capacity is currently underway with international researchers and international cooperation. “An experiment to inhibit the replication capacity of the phosphorous polymer against the actual infectious capacity using a confirmatory sample is currently being carried out in an Italian laboratory.”
Inpolymer is a field that has been constantly studied since the 1960s by Dr. Autor Kornberg, who won the Nobel Prize for Medicine in 1959. The study was started in 1997 by the German research team, focusing on the results of a study that several chain length phosphorous polymers have HIV-H1 (AIDS VIRUS), another virus, which inhibits infection.
Phosphorous polymers are linear polymers of at least 3 to up to 1000 phosphates (PO43-) connected to each other, and are found in almost all living organisms such as bacteria, fungi, plants and mammals.
A Heim Bio official said: “Inpolymers are important precursors to life.” ATP energy sources, energy sources, phosphate storage, metal ion binding and regulation of stress and survival. “It is an inorganic compound that has several functions, such as regulatory factors and factors, and it is possible to develop a variety of new drugs using genes that produce foreign substances and related genes.”
“Polymer research began in 1993 while attending Stanford School of Medicine in the United States,” said Kim, a polymer research expert. Said.
Meanwhile, HeimBio is developing a star cancer drug, “Starvanip (NYH817100),” which is a candidate for the next-generation cancer drug that starves and kills cancer cells only. It is undergoing Phase 1 clinical trials for several cancer patients who fail standard treatment in Korea at the Oncology Department of Yonsei University Severance Hospital.
[ad_2]
